Search | Clinical Trials Finder

Conditions: Type 1 Diabetes Mellitus
Interventions: T Cell Proliferation and Autoreactivity Assays, Cellular Immunoblot Assays, Tetramer Studies, Cytokine ELISPOT; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CTLA-4 Ig, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets; Diagnostic Test · Behavioral
Lead sponsor: MacroGenics; Industry
Eligibility: 10 Years to 37 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes (T1D)
Interventions: SAB-142, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 40 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm; Drug
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation; Biological · Other · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 30 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
Interventions: Imatinib Mesylate, Placebo (For imatinib mesylate); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions: CELZ-201 Administration, Control Group; Biological · Other
Lead sponsor: Creative Medical Technology Holdings Inc; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type I Diabetes
Interventions: OPT101, OPT101 Placebo to Match (PTM); Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab, Placebo; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 8 Years to 35 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 39
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more

Conditions: Type1diabetes
Interventions: Mixed Meal Tolerance Test; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
Interventions: Lactiplantibacillus plantarum, Placebo; Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes
Interventions: Sitagliptin and Lansoprazole, Placebo; Drug
Lead sponsor: Sanford Health; Other
Eligibility: 11 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota

Conditions: Type 1 Diabetes
Interventions: Autologous UCB, Omega 3 FA, Vitamin D; Biological · Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab Herold Regimen, Placebo, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 8 Years to 35 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 42
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more

Conditions: Type 1 Diabetes Mellitus
Interventions: teplizumab, Placebo; Biological
Lead sponsor: Provention Bio, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 34
States / cities: San Diego, California • San Francisco, California • Walnut Creek, California + 30 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Teplizumab, Placebo; Biological · Other
Lead sponsor: Provention Bio, a Sanofi Company; Industry
Eligibility: 9 Years to 19 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Walnut Creek, California + 22 more

Conditions: Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions: CNP-103, Placebo; Drug
Lead sponsor: COUR Pharmaceutical Development Company, Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Tucson, Arizona • San Diego, California • Walnut Creek, California + 27 more

Conditions: Diabetes Mellitus
Interventions: CLBS03 Low Dose, CLBS03 High Dose, Placebo; Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo; Biological · Dietary Supplement
Lead sponsor: Diamyd Medical AB; Industry
Eligibility: 12 Years to 28 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Newport Beach, California • Palo Alto, California • San Diego, California + 10 more

Conditions: Recent Onset type1 Diabetes
Interventions: Ladarixin, Placebo; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 14 Years to 45 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 20 more

Conditions: Diabetes type1
Interventions: AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose; Biological · Drug
Lead sponsor: Precigen Actobio T1D, LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more

Conditions: Type 1 Diabetes, Type1diabetes, Type 1 Diabetes Mellitus
Interventions: Visbiome, Placebo; Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetes Mellitus, Type 1
Interventions: IMCY-0098 450 μg, IMCY-0098 1350 μg, Placebo; Drug
Lead sponsor: Imcyse SA; Industry
Eligibility: 18 Years to 44 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 1 more

Search by objective public record fields.

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Development of Predictive Biomarkers

Reducing Innate Inflammation in New Onset Type 1 Diabetes

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

Cord Blood Plus Vitamin D and Omega 3s in T1D

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

Probiotics in Newly Diagnosed T1D

IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)